Bioventus Enters Contract with Aetna for DUROLANE

Bioventus has agreed to a U.S. contract with Aetna Medicare Advantage plans. Beginning January 1, 2024, over 3 million Aetna Medicare Advantage plan members will have access to DUROLANE to treat knee osteoarthritis (OA) pain.

DUROLANE, is a single-injection hyaluronic acid (HA)-based joint-fluid treatment for patients. DUROLANE will be one of...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us